Cumulocity Collaborates with Cisco to Streamline IoT Service and Application Delivery
Cumulocity, a leading mobile application enablement platform, today announced a collaboration with Cisco Jasper, Cisco’s IoT Cloud Business Unit, which will enable enterprises to streamline the delivery of IoT services and applications through connected devices. This collaboration allows Cumulocity to integrate the functionality of the Cisco Jasper IoT service platform, making it easy for joint customers to manage the delivery of IoT services and applications on the Cisco Jasper platform from within Cumulocity.
“Our goal is to make it as simple as possible for enterprises to deliver and manage IoT services while working within their IT solutions of choice,” said Macario Namie, Head of IoT Strategy at Cisco Jasper. “This integration gives Cumulocity customers access to their Cisco Jasper IoT service platform, and all of the visibility, intelligence and control they need to manage their connected services, from within Cumulocity.”
“Over 3,500 enterprises rely on the Cisco Jasper platform to deliver their IoT services, and many of those enterprises already utilize Cumulocity’s powerful application enablement platform to create, deploy and manage IoT applications that facilitate control of devices and their data,” said Jari Salminen, MD Sales & Strategic Partners at Cumulocity. “This collaboration enables our existing joint customers to easily manage their IoT connectivity, devices and data within a single solution, while also streamlining the ability for new customers to bring IoT services and applications to market.”
Control Center is the Cisco Jasper IoT service platform, a cloud-based IoT platform that enables companies of all sizes to rapidly and cost-effectively launch, manage and monetize IoT services for any connected device. The platform, which is easily configurable to meet the unique requirements of businesses across a broad range of industries, helps companies accelerate time-to-market, automate operations, optimize performance, troubleshoot and fix issues, and manage costs.
The Cumulocity IoT application enablement platform is designed to facilitate an open eco-system with free and immediate access to test accounts, open developer documentation and tools. The Cumulocity platform is a Software-as-a-Service (SaaS) offering, which is sold through mobile operators and is extensible to enterprise end customers. Through this integration, mobile operators who resell Cumulocity services will have the benefit of having Control Center functionality built into the Cumulocity-based applications they make available to their enterprise customers.
As businesses grow, Control Center makes it easy for them to seamlessly scale their IoT service businesses across the globe. Cisco Jasper collaborates with 27 mobile operator groups, representing more than 100 mobile operator networks worldwide, to deliver the benefits of the Cisco Jasper IoT solutions.
Cumulocity is the leading independent Application Enablement and Device Management platform for the Internet-of-Things (IoT) – since 2010. Cumulocity is an open platform, delivered via cloud or on-premise, that provides a complete feature set for rapidly developing and deploying IoT solutions. The key features include Data collection and Storage, Real-Time Analytics, Real-Time Visualization and Device Management. Scalability, security and reliability are critical in IoT solutions. Our origins as part of Nokia Siemens Networks, the world's mobile broadband specialist, gives us the experience of securely managing millions of devices without service interruptions.
For more information and to start your free trial visit www.cumulocity.com.
Cisco is the worldwide leader in IT that helps companies seize the opportunities of tomorrow by proving that amazing things can happen when you connect the previously unconnected. For ongoing news, please go to http://newsroom.cisco.com.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i